Want to see IN:ONESOURCE full AI Analyst Report?
Top Page
OneSource Specialty Pharma Limited
(ONESOURCE)
Select Model
Select Model
Rating:54Neutral
Price Target:
₹1,582.00
▲(2.70% Upside)
Action:N/A
Date:05/15/26
The score is held back primarily by weak fundamentals—sharp profitability deterioration and significant negative operating/free cash flow—despite strong FY2026 revenue growth. Technicals are supportive with an established uptrend and positive momentum, but an extremely high P/E and lack of dividend yield reduce the valuation score and cap the overall rating.
Positive Factors
Strong FY2026 revenue growth
A ~77% revenue surge in FY2026 reflects meaningful top-line momentum and growing commercial traction. Sustained revenue expansion provides a base to absorb costs, supports scale economics, and can enable future margin recovery if management converts product demand into higher-margin sales and tighter cost control.
Negative Factors
Negative operating and free cash flow
Sustained negative operating and free cash flow across two years, worsening in FY2026, signals persistent cash burn and that operations do not yet self-fund. This structural cash shortfall forces reliance on external financing, increases dilution or leverage risk, and constrains the firm’s ability to invest or weather shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong FY2026 revenue growth
A ~77% revenue surge in FY2026 reflects meaningful top-line momentum and growing commercial traction. Sustained revenue expansion provides a base to absorb costs, supports scale economics, and can enable future margin recovery if management converts product demand into higher-margin sales and tighter cost control.
Read all positive factors
OneSource Specialty Pharma Limited (ONESOURCE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹191.31B
Dividend YieldN/A
Average Volume (3M)3.94K
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue Growth47.33%
EPS Growth57.44%
CountryIN
Employees1,412
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)9.53
Shares Outstanding114,645,800
10 Day Avg. Volume3,856
30 Day Avg. Volume3,937
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.89
Price to Sales (P/S)11.87
P/FCF Ratio-24.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)38.15
Revenue Forecast (FY)₹22.08B
OneSource Specialty Pharma Limited Business Overview & Revenue Model
Company Description
OneSource Specialty Pharma Limited is a biopharmaceutical company focused on the discovery, advancement, production, and market introduction of biological drug products, primarily offered in diverse injectable formulations. The company conducts it...
How the Company Makes Money
null...
OneSource Specialty Pharma Limited Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
68
Positive
Cash Flow
29
Negative
| Breakdown | TTM | Mar 2025 | Mar 2025 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 8.02B | 14.22B | 14.45B |
| Gross Profit | 4.58B | 4.56B | 10.10B |
| EBITDA | 2.92B | 3.04B | 3.61B |
| Net Income | 1.09B | -738.03M | -2.10M |
Balance Sheet | |||
| Total Assets | 80.13B | 82.10B | 75.50B |
| Cash, Cash Equivalents and Short-Term Investments | 1.80B | 1.03B | 36.21M |
| Total Debt | 12.95B | 15.04B | 9.42B |
| Total Liabilities | 21.09B | 23.79B | 209.75M |
| Stockholders Equity | 59.04B | 58.31B | 58.81B |
Cash Flow | |||
| Free Cash Flow | -3.69B | -6.80B | -1.96B |
| Operating Cash Flow | -399.21M | -1.11B | -24.69M |
| Investing Cash Flow | -2.51B | -4.95B | -25.05M |
| Financing Cash Flow | 2.31B | 4.79B | 66.47M |
OneSource Specialty Pharma Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ₹208.85B | 28.11 | ― | 0.69% | 10.45% | -5.88% | |
62 Neutral | ₹161.69B | 23.84 | ― | 1.28% | 10.08% | 15.65% | |
60 Neutral | ₹234.18B | -68.13 | ― | 0.08% | -3.08% | -458.36% | |
60 Neutral | ₹198.43B | 31.91 | ― | 0.47% | 8.15% | 75.47% | |
59 Neutral | ₹207.45B | 109.88 | ― | 0.35% | 32.59% | 62.01% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₹191.31B | -262.05 | ― | ― | 47.33% | 57.44% |
* General Sector Average
IN:ONESOURCE
OneSource Specialty Pharma Limited
1,668.70
-329.70
-16.50%
IN:APLLTD
Alembic Pharmaceuticals Limited
822.60
-168.02
-16.96%
IN:ASTRAZEN
AstraZeneca Pharma India Limited
8,297.90
-809.04
-8.88%
IN:ERIS
Eris Lifesciences Ltd
1,432.00
-293.74
-17.02%
IN:PFIZER
PFIZER LIMITED
4,565.20
-1,106.43
-19.51%
IN:PPLPHARMA
Piramal Pharma Limited
175.90
-26.47
-13.08%
OneSource Specialty Pharma Limited Corporate Events
OneSource to Manufacture Dr. Reddy’s Generic Ozempic for Canada
Apr 29, 2026
OneSource Specialty Pharma Limited said partner Dr. Reddy’s Laboratories has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of diabetes and weight-loss drug Ozempic. OneSource serves as the CD...
OneSource Specialty Pharma Wins EU GMP Nod for Bangalore Sterile Facility
Apr 28, 2026
OneSource Specialty Pharma Limited’s Sterile Product Division facility in Bangalore has received an EU Good Manufacturing Practice (GMP) Certificate of Compliance for sterile products from the German state authority of Schleswig-Holstein, fo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.